Head-to-head · WeighScore
Claya vs Willow
The verdict
Claya takes it — 62.8/100 to 58.2/100.
Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Claya | Willow |
|---|---|---|
| WeighScore | 62.8/100 | 58.2/100 |
| Grade | C | C |
| Scorecard rank | #268 | #377 |
| Semaglutide | $299/mo (compounded) | $299/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (compounded) | $399/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #268 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
Where it loses points
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Graded #377 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.